Is advanced breast cancer really increasing in younger women?

Article

Debu Tripathy blog image

A high-profile article was published recently showing a small but statistically significant increase in the rate younger women, aged 25-39 diagnosed with breast cancer with distant metastasis. Published in the Journal of the American Medical Association (JAMA), it's made quite an impact (you can read the full article here). But what are we to make of this, and should anything be done? Should we be alarmed? Well, probably not at this point – it may not even be real. First of all, this information comes from cancer registry data, which is very good at capturing data at the time of diagnosis, but not long-term follow-up (other than death). So this is really looking at the less common situation of women who actually present with metastases at the time of their original diagnosis – which only happens about 5 to 10 percent of the time, and perhaps more so in women who do not have access to health care and present with higher stage cancers.Second, the overall numbers are very small – going from 1.53 to 2.21 cases per 100,000 women per year from 1976 to 2009. In the same period of time, there was an also an increase, although small, in this measure for women age 40-54, but not for those age 55 to 84. Finally, there has not been what would be an expected corresponding disproportional increase in death due to breast cancer reported among younger women over this timeframe, so other causes, such as more aggressive use of CT and PET scans in younger women could account for this - such that the true incidence is not changing, we are just being made aware of it more due to scanning.Of course, these data do not tell us WHY we might be seeing this increase, or whether we can even verify it. So for the moment we need to look at other information sources and worldwide statistics. We also have to determine if there might be addressable causes, such as limitations of access to care in this population, known as AYA (adolescent and young adult). AYAs do have more barriers to care and other studies have shown that they have not benefited as much with improvements over time in cancer mortality compared with pediatric and older adult populations. More AYAs have no or limited insurance. They are also more mobile and their medical follow-up may be inferior. While this report should not cause alarm or even affect any of our care guidelines, it may be a wake-up call to truly understand what might be driving this.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content